IRF8 RRV

IRF8 RRV is an investigational gene therapy consisting of a retroviral replicating vector (RRV) that encodes the Interferon Regulatory Factor 8 (IRF8) transgene. IRF8 is a transcription factor and master regulator of type 1 conventional dendritic cell (cDC1) development. In the context of glioblastoma (GBM), the vector is designed to selectively infect and replicate in proliferating cells, including both tumor cells and immature myeloid cells (IMCs) within the immunosuppressive tumor microenvironment. By delivering IRF8, the therapy aims to reprogram these IMCs into functional antigen-presenting cells (APCs), thereby enhancing anti-tumor T cell responses and reducing local immunosuppression. Preclinical studies in murine glioblastoma models have demonstrated that IRF8 RRV can significantly extend survival and increase the infiltration of cytotoxic CD8+ T cells and cDC1s.

Other names

retroviral replicating vector expressing IRF8